BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 37842234)

  • 1. Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma.
    Astore S; Baciarello G; Cerbone L; Calabrò F
    Cancer Drug Resist; 2023; 6(3):517-546. PubMed ID: 37842234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.
    Sekino Y; Teishima J; Liang G; Hinata N
    Int J Urol; 2022 Dec; 29(12):1419-1428. PubMed ID: 36122306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
    Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging resistance
    Roy AM; George S
    Cancer Drug Resist; 2023; 6(3):642-655. PubMed ID: 37842239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.
    Lai Y; Zhao Z; Zeng T; Liang X; Chen D; Duan X; Zeng G; Wu W
    Cancer Cell Int; 2018; 18():31. PubMed ID: 29527128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.
    Sweeney PL; Suri Y; Basu A; Koshkin VS; Desai A
    Cancer Drug Resist; 2023; 6(4):858-873. PubMed ID: 38239394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
    Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
    Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
    Tannir N; Hammers H; Amin A
    Curr Med Res Opin; 2018 May; 34(5):825-831. PubMed ID: 29297707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.
    Kamli H; Li L; Gobe GC
    Ochsner J; 2019; 19(2):138-151. PubMed ID: 31258426
    [No Abstract]   [Full Text] [Related]  

  • 11. IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma.
    Rizzo M; Varnier L; Pezzicoli G; Pirovano M; Cosmai L; Porta C
    Front Oncol; 2022; 12():990568. PubMed ID: 36059687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
    Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
    Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
    Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
    Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.
    Mollica V; Di Nunno V; Gatto L; Santoni M; Scarpelli M; Cimadamore A; Lopez-Beltran A; Cheng L; Battelli N; Montironi R; Massari F
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31207938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
    Vano YA; Elaidi R; Bennamoun M; Chevreau C; Borchiellini D; Pannier D; Maillet D; Gross-Goupil M; Tournigand C; Laguerre B; Barthélémy P; Coquan E; Gravis G; Houede N; Cancel M; Huillard O; Beuzeboc P; Fournier L; Méjean A; Cathelineau X; Doumerc N; Paparel P; Bernhard JC; de la Taille A; Bensalah K; Tricard T; Waeckel T; Pignot G; Braychenko E; Caruso S; Sun CM; Verkarre V; Lacroix G; Moreira M; Meylan M; Bougouïn A; Phan L; Thibault-Carpentier C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C; Oudard S
    Lancet Oncol; 2022 May; 23(5):612-624. PubMed ID: 35390339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
    Liu W; Ren D; Xiong W; Jin X; Zhu L
    J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line treatment in renal cell carcinoma: clinical experience and decision making.
    Guadalupi V; Cartenì G; Iacovelli R; Porta C; Pappagallo G; Ricotta R; Procopio G
    Ther Adv Urol; 2021; 13():17562872211022870. PubMed ID: 34211586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
    Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
    J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.